Engineering challenges for brain tumor immunotherapy. 2017

Johnathan G Lyon, and Nassir Mokarram, and Tarun Saxena, and Sheridan L Carroll, and Ravi V Bellamkonda
Department of Biomedical Engineering, Pratt School of Engineering, Duke University, 101 Science Drive, Durham, NC 27708-0271, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory School of Medicine, UA Whitaker Building, 313 Ferst Drive, Atlanta, GA 30332, USA.

Malignant brain tumors represent one of the most devastating forms of cancer with abject survival rates that have not changed in the past 60years. This is partly because the brain is a critical organ, and poses unique anatomical, physiological, and immunological barriers. The unique interplay of these barriers also provides an opportunity for creative engineering solutions. Cancer immunotherapy, a means of harnessing the host immune system for anti-tumor efficacy, is becoming a standard approach for treating many cancers. However, its use in brain tumors is not widespread. This review discusses the current approaches, and hurdles to these approaches in treating brain tumors, with a focus on immunotherapies. We identify critical barriers to immunoengineering brain tumor therapies and discuss possible solutions to these challenges.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014612 Vaccines Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases. Vaccine
D057005 Bioengineering The application of engineering principles and methods to living organisms or biological systems. Bio-Engineering,Bio engineering,Biological Engineering,Bio engineerings,Bioengineerings,Engineering, Biological,engineering, Bio,engineerings, Bio
D019264 Adoptive Transfer Form of passive immunization where previously sensitized immunologic agents (cells or serum) are transferred to non-immune recipients. When transfer of cells is used as a therapy for the treatment of neoplasms, it is called adoptive immunotherapy (IMMUNOTHERAPY, ADOPTIVE). Adoptive Cell Transfer,Adoptive Cell Transfers,Adoptive Transfers,Cell Transfer, Adoptive,Cell Transfers, Adoptive

Related Publications

Johnathan G Lyon, and Nassir Mokarram, and Tarun Saxena, and Sheridan L Carroll, and Ravi V Bellamkonda
October 2021, Der Nervenarzt,
Johnathan G Lyon, and Nassir Mokarram, and Tarun Saxena, and Sheridan L Carroll, and Ravi V Bellamkonda
October 2020, Neuro-oncology practice,
Johnathan G Lyon, and Nassir Mokarram, and Tarun Saxena, and Sheridan L Carroll, and Ravi V Bellamkonda
January 2024, Advanced science (Weinheim, Baden-Wurttemberg, Germany),
Johnathan G Lyon, and Nassir Mokarram, and Tarun Saxena, and Sheridan L Carroll, and Ravi V Bellamkonda
October 2017, Trends in cancer,
Johnathan G Lyon, and Nassir Mokarram, and Tarun Saxena, and Sheridan L Carroll, and Ravi V Bellamkonda
July 2015, Journal of neuro-oncology,
Johnathan G Lyon, and Nassir Mokarram, and Tarun Saxena, and Sheridan L Carroll, and Ravi V Bellamkonda
January 2023, Microsystems & nanoengineering,
Johnathan G Lyon, and Nassir Mokarram, and Tarun Saxena, and Sheridan L Carroll, and Ravi V Bellamkonda
January 2024, Journal of immunology (Baltimore, Md. : 1950),
Johnathan G Lyon, and Nassir Mokarram, and Tarun Saxena, and Sheridan L Carroll, and Ravi V Bellamkonda
January 2021, iScience,
Johnathan G Lyon, and Nassir Mokarram, and Tarun Saxena, and Sheridan L Carroll, and Ravi V Bellamkonda
December 2021, Biochimica et biophysica acta. Reviews on cancer,
Johnathan G Lyon, and Nassir Mokarram, and Tarun Saxena, and Sheridan L Carroll, and Ravi V Bellamkonda
July 1988, No to shinkei = Brain and nerve,
Copied contents to your clipboard!